Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 415 results for cardiovascular disease

  1. What is the effectivness of statin treatment in older people?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  2. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA663

  3. What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

    Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  4. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

    Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA306

  5. Automated blood pressure monitoring in people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial fibrillation?

    monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  6. Blood pressure targets for people with aortic aneurysm: What are the optimal blood pressure targets in adults with hypertension and aortic aneurysm, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  7. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

    Clinical guideline
    Published
    13 November 2013

  8. Blood pressure targets for people with prior ischaemic or haemorrhagic stroke: What are the optimal blood pressure targets in adults with prior ischaemic or haemorrhagic stroke, and does this vary by age?

    the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...

    Research recommendation
    Published
    11 April 2022

  9. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA959

  10. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    . Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    3 May 2024

  11. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    adults unless contraindicated (adults over 65 or with a history of cardiovascular disease). Although evidence about dosing was very...

    Research recommendation
    Published
    10 February 2020

  12. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Clinical guideline
    Published
    18 July 2014

  13. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...

    Research recommendation
    Published
    9 June 2015

  14. Obesity in adults: prevention and lifestyle weight management programmes (QS111)

    This quality standard covers preventing adults (aged 18 and over) from becoming overweight or obese. It includes strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for adults who are overweight or obese. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 January 2016
    View quality statements

    Sections for QS111

  15. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015